Harry J. Leonhardt
2021 - Poseida Therapeutics
In 2021, Harry J. Leonhardt earned a total compensation of $1.4M as General Counsel, Chief Compliance Officer and Corporate Secretary at Poseida Therapeutics.
Compensation breakdown
| Non-Equity Incentive Plan | $149,580 |
|---|---|
| Option Awards | $867,018 |
| Salary | $415,500 |
| Other | $9,252 |
| Total | $1,441,350 |
Leonhardt received $867K in option awards, accounting for 60% of the total pay in 2021.
Leonhardt also received $149.6K in non-equity incentive plan, $415.5K in salary and $9.3K in other compensation.
Rankings
In 2021, Harry J. Leonhardt's compensation ranked 7,413th out of 12,415 executives tracked by ExecPay. In other words, Leonhardt earned more than 40.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 7,413 out of 12,415 | 40th |
Division Manufacturing | 3,260 out of 5,505 | 41st |
Major group Chemicals And Allied Products | 1,442 out of 2,375 | 39th |
Industry group Drugs | 1,285 out of 2,096 | 39th |
Industry Biological Products, Except Diagnostic Substances | 296 out of 449 | 34th |
Source: SEC filing on April 26, 2023.
Leonhardt's colleagues
We found three more compensation records of executives who worked with Harry J. Leonhardt at Poseida Therapeutics in 2021.
News
Poseida Therapeutics CEO Mark Gergen's 2022 pay jumps 55% to $4.4M
April 26, 2023
Poseida Therapeutics CEO Eric Ostertag's 2021 pay jumps 633% to $6.3M
April 27, 2022
Halozyme Therapeutics CEO Helen Torley's 2019 pay rises 1% to $5.9M
March 20, 2020
Halozyme Therapeutics CEO Helen Torley's 2018 pay rises 12% to $5.8M
March 22, 2019